Name
RF01-03 - PARSIFAL-LONG: Extended follow-up of hormone receptor-positive/HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs letrozole and palbociclib in the PARSIFAL study (China)
Date & Time
Wednesday, December 20, 2023
Speakers
Virtual Session Link